Publications by authors named "Elena Vladislavovna Morozova"
Article Synopsis
- This analysis reviewed trends in 5185 hematopoietic cell transplantations (HCT) between 1990 and 2022, including 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) transplants.
- There was a significant improvement in event-free survival (EFS) for both autoHCT and alloHCT over time, attributed to a decrease in relapse rates and non-relapse mortality, respectively.
- Specific survival improvements were noted for various conditions, with autoHCT showing better outcomes in Hodgkin's disease and multiple myeloma, while alloHCT advancements were observed mainly in leukemia and lymphomas.
A number of sequencing studies identified the prognostic impact of somatic mutations in myelodysplastic syndrome (MDS). However the majority of them focused on methylation regulation, apoptosis and proliferation genes. Despite the number of experimental studies published on the role of micro-RNA processing and checkpoint genes in the development of MDS, the clinical data about mutational landscape in these genes is limited.
View Article and Find Full Text PDFA Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
Acta Haematol
April 2021
Introduction: This prospective study evaluated a calcineurin inhibitor-free graft-versus-host disease (GVHD) prophylaxis regimen of ruxolitinib in combination with post-transplant cyclophosphamide (PTCy). Patents and Methods: Twenty patients with primary or secondary myelofibrosis were prospectively enrolled. Reduced intensity conditioning was performed, followed by allogeneic stem cell transplantation from related (n = 7) or unrelated (n = 13) donors.
View Article and Find Full Text PDFSplenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation.
Hematol Oncol Stem Cell Ther
September 2019
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only treatment option with curative potential in patients with myelofibrosis (MF). The aim of our study was to evaluate the safety of splenectomy before alloHSCT in MF patients who failed to achieve significant spleen response after ruxolitinib therapy.
Methods: Splenectomy was performed in 12 patients for alloHSCT with myelofibrosis-primary (6 patients), post-polycythemia vera (3 patients).